Cloning and functional characterization of the rabbit C-C chemokine receptor 2
© Lu et al; licensee BioMed Central Ltd. 2005
Received: 12 April 2005
Accepted: 07 July 2005
Published: 07 July 2005
CC-family chemokine receptor 2 (CCR2) is implicated in the trafficking of blood-borne monocytes to sites of inflammation and is implicated in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and atherosclerosis. The major challenge in the development of small molecule chemokine receptor antagonists is the lack of cross-species activity to the receptor in the preclinical species. Rabbit models have been widely used to study the role of various inflammatory molecules in the development of inflammatory processes. Therefore, in this study, we report the cloning and characterization of rabbit CCR2. Data regarding the activity of the CCR2 antagonist will provide valuable tools to perform toxicology and efficacy studies in the rabbit model.
Sequence alignment indicated that rabbit CCR2 shares 80 % identity to human CCR2b. Tissue distribution indicated that rabbit CCR2 is abundantly expressed in spleen and lung. Recombinant rabbit CCR2 expressed as stable transfectants in U-937 cells binds radiolabeled 125I-mouse JE (murine MCP-1) with a calculated K d of 0.1 nM. In competition binding assays, binding of radiolabeled mouse JE to rabbit CCR2 is differentially competed by human MCP-1, -2, -3 and -4, but not by RANTES, MIP-1α or MIP-1β. U-937/rabbit CCR2 stable transfectants undergo chemotaxis in response to both human MCP-1 and mouse JE with potencies comparable to those reported for human CCR2b. Finally, TAK-779, a dual CCR2/CCR5 antagonist effectively inhibits the binding of 125I-mouse JE (IC50 = 2.3 nM) to rabbit CCR2 and effectively blocks CCR2-mediated chemotaxis.
In this study, we report the cloning of rabbit CCR2 and demonstrate that this receptor is a functional chemotactic receptor for MCP-1.
Chemokine receptors are seven-transmembrane G-protein coupled receptors that direct the migration of various immune cells to the sites of inflammation in addition to their pivotal role in maintaining immune cell homeostasis in various lymphoid compartments [1, 2]. Chemokines (8–14 kDa molecular weight), the ligands of chemokine receptors, are broadly classified based on the positioning of the two conserved cysteines into the CC, CXC, C or CX3C family . Binding of chemokines to their cognate receptors on immune cells triggers a signaling cascade primarily mediated by the Gαi family of G proteins leading to a variety of cell effector functions including chemotaxis, degranulation, and release of pro-inflammatory cytokines such as TNF α .
The CC family chemokine receptor 2 (CCR2) is primarily expressed in almost all circulating monocytes. CCR2 is believed to mediate extravasation of blood monocytes to the sites of inflammation [5–7] and is implicated in the pathogenesis of several inflammatory diseases such as rheumatoid arthritis, multiple sclerosis and atherosclerosis [8, 9]. MCP subfamily members, namely MCP-1, -2, -3, and -4, bind to CCR2 with high affinity [7, 10, 11]. Several studies involving genetic deletion of CCR2 or MCP-1, and antibody neutralization studies of MCP-1 have clearly established the critical role of the CCR2/MCP-1 axis in mediating several key pathogenic events in animal models of multiple sclerosis and atherosclerosis.
The major challenge in the development of small molecule chemokine receptor antagonists is the lack of cross-species activity to the receptor in the preclinical species. For example, BX-471, a small molecule antagonist for CCR1, exhibits low nano-molar affinity to the human receptor but has sub-micromolar to high micromolar affinity to the rat and mouse CCR1 receptors, respectively . Importantly, BX-471 had intermediate affinity to the rabbit CCR1 receptor . This imposes significant challenges to compound testing in efficacy and toxicology studies in the preclinical models.
In recent years, rabbits have been used to study the pathogenesis of inflammatory disease model. It has been recently shown that the therapeutic potential of thiazolidinediones in rabbit model of balloon injury and re-endothelialization is associated with a decrease in MCP-1 expression . In addition, the efficacy of a CXCR2 antagonist has been successfully demonstrated in a chronic antigen induced arthritis model . Moreover, CCR1 antagonists have therapeutic benefit in a rabbit allograft rejection model . In the present study we report the cloning and functional characterization of the rabbit CCR2. We also demonstrate that the recently reported CCR2/CCR5 dual antagonist, TAK-779, exhibits high level of potency against rabbit CCR2 in both binding and chemotaxis assays.
Results and Discussion
Cloning and expression analysis of rabbit CCR2
Radioligand binding studies in rabbit CCR2 expressing cells
Functional characterization of Rabbit CCR2 stable cell line
In summary, we have cloned the full-length rabbit CCR2 cDNA and proved that the receptor is functional by expressing rabbit CCR2 in U-937 cells. The sequence of rabbit CCR2 will provide additional insight into the molecular evolution of chemokine receptors in different species. More importantly, the data obtained on cross-species activity of the CCR2 antagonist will provide valuable tools to perform toxicology and efficacy studies in the rabbit model.
Recombinant human chemokines (MCP-1, -2, -3, -4, RANTES, MIP-1α, MIP-1β) were purchased from Pepro Tech (Rocky Hill, NJ). Mouse JE and human SDF-1α were obtained from R&D Systems (Minneapolis, MN). Radiolabeled ligands (125I-human MCP-1 and 125I-mouse JE) were purchased from Perkin Elmer (Boston, MA). RPMI 1640, bovine albumin serum (BSA) and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) were purchased from Sigma (Gaithersburgh, MD). Polymeric chain reaction (PCR) and Taqman primers were purchased from Qiagen (Valencia, CA). The CCR5/CCR2 dual antagonist TAK-779 was synthesized as described elsewhere .
Rabbit cDNA cloning
Total RNA was prepared from the spleen of New Zealand white rabbits by the Trizol method and the cDNA was transcribed by using SuperScript™ First-Strand Synthesis System for RT-PCR (Invitrogen, Carlson, CA). Then the cDNA was amplified by PCR by using conserved primers (primer 1: 5'-GTATTCATCTTTGGTTTTGTGGGCAACATG-3' and primer 2: 5'-CAAAGGTAACTGTCCTGGCTTTTAAAGCAA-3'). The resultant PCR fragment was sequenced and this information was used to design the rabbit CCR2 gene specific primers. Rabbit CCR2 gene specific primers were used to amplify two fragments of rabbit cDNA by 5'- and 3'- rapid amplification of cDNA ends (RACE) using SMART RACE cDNA Amplification Kit (Clonetech, Palo Alto, CA). The sequence information from 5'- and 3'- RACE products was further used to design two primers (5'-GGTTGCTGAGAAGCCTGACACGC-3', and 5'-CAGGTCTGTATTCTTCAACAAGCCCTCG-3') out of start and stop codons, and full-length rabbit CCR2 cDNA was cloned using PCR amplification. The final PCR product with corresponding size was cloned to PCRII-TAPO (Invitrogen) and sequenced.
Rabbit cDNA from brain, heart, liver, lung, spleen and testis were quantitated for expression levels of CCR2 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) by Taqman method. TaqMan primers and probes were designed using the Primer Express Computer Program (Applied Biosystems, Foster City, CA). The forward and reverse primers and probe selected for rabbit CCR2 are: 5'-catgacacactgctgcatcaac-3', 5'-gagaggtagctccggaacttctc-3' and 5'-[6-FAM]-ccgtggtctacgccttcgtcgg-[TAMRA-6-FAM]-3'. The forward, reverse primers and probe selected for rabbit GAPDH are: 5'-ggatttggccgcattgg-3', 5'-caacatccactttgccagagttaa-3' and 5'-[6-FAM]-cgcctggtcaccagggctgct-[TAMRA-6-FAM]-3'. Amplification mixture contained a total volume of 10 μl with 6 μl of TaqMan universal PCR master mixture (300 nM forward primer, 300 nM reverse primer, and 900 nM probe) and 4 μl of diluted samples. Taqman amplification was conducted on a ABI PRISM 7900HT Sequence Detector System (Applied Biosystems, Foster City, CA) with the following thermal profile: 1 cycle each of 50°C for 2 minutes and 95°C for 10 minutes followed by 40 cycles each of 95°C for 15 seconds and 60°C for 1 minute. Data was analyzed using a built-in standard curve method.
Generation of retrovirus infected rabbit CCR2 stable cell line
Rabbit cDNA described above was amplified by PCR with primer 11: 5'-ggaggcagatct cgaacaggcagctggcgg-3' and primer 12: 5'-ttattggaattc caagccgacggctgtcca-3' (underlined nucleotides are the cleavage sites of Bgl II and EcoR I, respectively). The resulted PCR fragment was digested with Bgl II and EcoR I, and then subcloned into the corresponding site of pMSCVpuro retroviral expression vector (BD Biosciences, CA). Lipofectamine-mediated transfection was carried out in the AmphoPack 293 packaging cell line (BD Biosciences, CA) with a full-length cDNA for rabbit CCR2 in the retroviral expression vector pMSCVpuro, containing a puromycin resistance selection marker. Thirty six hours after transfection, the pool of viral supernatant was recovered from the packaging cells, centrifuged, and polybreen was added to a final concentration of 8 μg/ml. The viral supernatant was then added to parental U-937 cells in a tissue culture treated flask and the infection was allowed to proceed for 7 hours. At this time, additional medium was added to the packaging cells to generate more virus. After 7 hours, the second pool of viral supernatant was prepared as the first, except with 4 μg/ml polybreen. U-937 cells were resuspended in this viral supernatant and the infection was allowed to proceed overnight. Then the U-937 cells were placed into fresh medium without any selection. After 18 hours, the medium was changed to selection medium containing 0.4 μg/ml puromycin. The pool of stably transfected clones was propagated for binding and chemotaxis assays.
Equilibrium binding assays
Equilibrium binding assay was conducted in RPMI 1640 medium with 10 mM HEPES and 0.2% BSA in room temperature with constant shaking for 2 hours. Reaction mixture contained a total volume of 100 μl with various concentrations of 125I-labeled ligands (125I-human MCP-1 or 125I-mouse JE), U-937/rabbit CCR2 stable transfectants (105 cells /well for 125I-human MCP-1 and 104 cells /well for 125I-mouse JE) in the presence or absence of corresponding cold ligand. Nonspecific binding was determined by 100-fold excess of cold ligand. Reactions were stopped by separation using the glass fiber filter (Wallac Printed Filtermat A) on a Tomtec Harvester 96-2 (Hamden, CT). Filters were subsequently washed 5 times with wash buffer (10 mM HEPES, 500 mM NaCl, pH 7.4) to remove the unbound radioligand. Finally, bound radioligand was quantitated using a liquid scintillation counter (Wallac 1205 Betaplate, Perkin Elmer). Dissociation constant (K d ) and maximum binding (B max ) were calculated by non-linear regression with Graphpad Prism 4.01 (San Diego, CA).
Competition binding assays
The assay was conducted under the identical conditions as saturation binding assay described above with the radiolabeled ligand concentration fixed (0.11 nM 125I-mouse JE) in the presence of various concentrations of unlabeled chemokines or TAK-779. Values of IC50 were calculated by fitting the competition curves with Graphpad Prism 4.01.
Chemotaxis assay was performed as described elsewhere  with a few modifications. Parental U-937 or U-937/rabbit CCR2 stable transfectants were harvested, counted and resuspended at a final cell density of 5 × 106 /ml in chemotaxis buffer (RPMI 1640 medium, containing 0.3% BSA and 1 mM HEPES). Chemokines were diluted to 1000 ng/ml stock and serially diluted (1:3) in migration buffer in a Costar 96 well plate (Cat #3790, Costar, Corning NY). Thirty microliters of each chemokine dilution were transferred to the corresponding well in the bottom chamber of a ChemoTX 96 well migration plate (5 μM pore size; Neuroprobe, Gaithersburg, MD). The ChemoTX filter unit was assembled and 50 μl of cells were added to the top chamber and incubated for 2.5 hours. Plates were then removed and cells were aspirated off the filter top. The cells that had migrated to the bottom chamber were pulsed with 5 μl of Aqueous One Solution (Promega, Madison, WI) and incubated for an additional 30–60 minutes at 37°C. Plates were shaken gently to permit uniform mixing and read at 490 nm in a Spectramax Plus reader (Molecular Dynamics, Piscataway, NJ). Cell standard curves were incorporated into the bottom of each plate with cell number ranges from 0–150,000 cells/well. The results were expressed as percent cell migration versus chemokine concentration. For compound testing, TAK-779 was diluted in DMSO at various concentrations and added to both the top and bottom chambers and chemotaxis assay was performed in the presence of 4 nM of mouse JE as described above.
CC chemokine receptor 2
monocyte chemoattactant protein
regulated on activation-regulated chemokine
macrophage inflammatory protein
rapid amplification of cDNA ends, HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
bovine serum albumin
polymerase chain reaction.
- Rollins BJ: Chemokines. Blood. 1997, 90: 909-928.PubMedGoogle Scholar
- Fernandez EJ, Lolis E: Structure, function, and inhibition of chemokines. Annu Rev of Pharmacol Toxicol. 2002, 42: 469-499. 10.1146/annurev.pharmtox.42.091901.115838.View ArticleGoogle Scholar
- Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annual Review of Immunology. 2000, 18: 217-242. 10.1146/annurev.immunol.18.1.217.View ArticlePubMedGoogle Scholar
- Stievano LPE, Amadori A: C and CX3C chemokines: cell sources and physiopathological implications. Crit Rev Immunol. 2004, 24: 205-228. 10.1615/CritRevImmunol.v24.i3.40.View ArticlePubMedGoogle Scholar
- Wong L-M, Myers SJ, Tsou C-L, Gosling J, Arai H, Charo IF: Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem. 1997, 272: 1038-1045. 10.1074/jbc.272.2.1038.View ArticlePubMedGoogle Scholar
- Yamagami S, Tokuda Y, Ishii K, Tanaka H, Endo N: CDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor. Biochem and Biophys Res Commun. 1994, 202: 1156-1162. 10.1006/bbrc.1994.2049.View ArticleGoogle Scholar
- Charo I, Myers S, Herman A, Franci C, Connolly A, Coughlin S: Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. PNAS. 1994, 91: 2752-2756.PubMed CentralView ArticlePubMedGoogle Scholar
- Gerard C, Rollins BJ: Chemokines and disease. Nat Immunol. 2001, 2: 108-115. 10.1038/84209.View ArticlePubMedGoogle Scholar
- Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res. 2004, 95: 858-866. 10.1161/01.RES.0000146672.10582.17.View ArticlePubMedGoogle Scholar
- Franci C, Wong L, Van Damme J, Proost P, Charo I: Monocyte chemoattractant protein-3, but not monocyte chemoattractant protein-2, is a functional ligand of the human monocyte chemoattractant protein-1 receptor. J Immunol. 1995, 154: 6511-6517.PubMedGoogle Scholar
- Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OMZ, Wang JM: Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2b as its functional receptors. J Biol Chem. 1997, 272: 11682-11685. 10.1074/jbc.272.18.11682.View ArticlePubMedGoogle Scholar
- Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S, Bauman JG, Islam I, Ghannam A, Buckman B, Shaw K, Wei G-P, Xu W, Zhao Z, Ho E, Shen J, Oanh H, Subramanyam B, Vergona R, Taub D, Dunning L, Harvey S, Snider RM, Hesselgesser J, Morrissey MM, Perez HD, Horuk R: Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem. 2000, 275: 19000-19008. 10.1074/jbc.M001222200.View ArticlePubMedGoogle Scholar
- Horuk R, Shurey S, Ng HP, May K, Bauman JG, Islam I, Ghannam A, Buckman B, Wei GP, Xu W: CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. Immunology Letters. 2001, 76: 193-201. 10.1016/S0165-2478(01)00172-9.View ArticlePubMedGoogle Scholar
- Tanaka T, Fukunaga Y, Itoh H, Doi K, Yamashita J, Chun T-H, Inuoe M, Masatsugu K, Saito T, Sawada N, Sakaguchi S, Arai H, Nakao K: Therapeutic potential of thiazolidinediones in activation of peroxisome proliferator-activated receptor γ for monocyte recruitment and endothelial regeneration. Eur J Pharmacol. 2005, 508: 255-265. 10.1016/j.ejphar.2004.10.056.View ArticlePubMedGoogle Scholar
- Podolin P, Bolognese BJ, Foley JJ, Schmidt DB, Buckley PT, Widdowson KL, Jin Q, White JR, Lee JM, Goodman RB, Hagen TR, Kajikawa O, Marshall LA, Hay DWP, Sarau HM: A potent and selective nonpeptide anatagonist of CXCR2 inhibits acute and chronic models of arthritis in the rabbit. J Immunol. 2002, 169: 6435-6444.View ArticlePubMedGoogle Scholar
- Shi X, Liu S, Xiangyu J, Zhang J, Liu S, Liu C: Structural analysis of human CCR2b and primate CCR2b by modeling and molecular dynamics simulation. J Mol Model (online). 2002, 8: 217-222. 10.1007/s00894-002-0089-6.View ArticleGoogle Scholar
- Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M: A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. PNAS. 1999, 96: 5698-5703. 10.1073/pnas.96.10.5698.PubMed CentralView ArticlePubMedGoogle Scholar
- Chung CD, Kuo F, Kumer J, Motani AS, Lawrence CE, Henderson WR, Venkataraman C: CCR8 Is not essential for the development of inflammation in a mouse model of allergic airway disease. J Immunol. 2003, 170: 581-587.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.